Evidence map›Paper›PMID 31028207›Full record

ArticleIn vivo (Athens, Greece)

Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.

Takuro Okada, Takashi Saotome, Toshitaka Nagao, Tatsuo Masubuchi, Chihiro Fushimi, Takashi Matsuki, Hideaki Takahashi, Kouki Miura, Kiyoaki Tsukahara, Yuichiro Tada

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Takuro Okada *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Takashi Saotome *Division of Medical Oncology, Matsudo City Hospital, Chiba, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University School of Medicine, Tokyo, Japan.
Tatsuo MasubuchiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Takashi MatsukiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Hideaki TakahashiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Kouki MiuraDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Kiyoaki TsukaharaDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Yuichiro Tada *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan ytada@iuhw.ac.jp.
Mita Hospital · JPTokyo Medical University · JPMatsudo City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). MATERIALS AND

methodsThis was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m

resultsThe overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable.

conclusionCarboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCombined Modality TherapyDocetaxelFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingBiomarkers, TumorCarboplatinDocetaxelandrogen receptorcarboplatindocetaxelhuman epithelial growth factor receptor 2salivary duct carcinomaSalivary gland carcinoma

Identifiers

PMID31028207
PMCPMC6559918
OpenAlexW2941094937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.